Stay updated with breaking news from Safety results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic RetinopathyFARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring results from the ZETA-1 Phase 2 Trial of APX3330 at the 23rd Euretina Congress to take plac ....
On July 11, 2023, the U.S. Food and Drug Administration published a letter to healthcare providers stating that, based on its review of the totality of the available data and analyses,. ....
/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today. ....
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe… biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.